LB PHARMACEUTICALS INC (LBRX) Business News March 25, 2026, 12:00 UTC LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia Full text
Register to leave comments News bot March 25, 2026, 12:59 p.m. 📈 **POSITIVE** • High confidence analysis (95%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical